Benitec Biopharma(US:BNTC)2025-11-14 22:31Clinical Trial Results - Benitec Biopharma achieved a 100% responder rate in Cohort 1 of the Phase 1b/2a trial for BB-301, with all six patients meeting the formal statistical criteria for response[1]. - The first patient in Cohort 2 of the BB-301 trial was successfully treated in Q4 2025[1]. - The FDA granted Fast Track Designation to BB-301 for the treatment of dysphagia associated with Oculopharyngeal Muscular Dystrophy[5]. Financial Performance - Total expenses for Q1 2026 were $9.8 million, up from $5.8 million in Q1 2025, with general and administrative expenses increasing to $6.4 million from $2.2 million[6]. - The net loss attributable to shareholders for Q1 2026 was $9.0 million, or $(0.22) per share, compared to a net loss of $5.1 million, or $(0.18) per share in Q1 2025[7]. - Benitec's total comprehensive loss for Q1 2026 was $8.9 million, compared to a loss of $5.2 million in Q1 2025[7]. - Benitec's accumulated deficit as of September 30, 2025, was $(237.1) million, up from $(228.2) million as of June 30, 2025[9]. Funding and Financial Strategy - The company raised approximately $100 million in an oversubscribed public offering to fund the advancement of the BB-301 program[2]. - The company plans to use net proceeds from the recent financing to support the continued development and registration of BB-301, working capital, and other general corporate purposes[5]. - As of September 30, 2025, the company had $94.5 million in cash and cash equivalents[7].